triumph-1 retatrutide TRIUMPH-1: Phase 3 Topline Results for in Obesity The data just dropped —

Expert Opin Ther Targets (2018) 22(3):20116

Valued at approximately $1.5 billion in 2024, the market is projected to reach around $5.9 billion by 2034, expanding at a strong CAGR of about 13.7%

Every vial goes through careful testing and quality control processes

Importantly, a randomized controlled trial demonstrated that L-carnitine supplementation reduces the intramyocellular-to-extramyocellular lipid ratio in NAFLD patients, suggesting enhanced clearance and utilization of intracellular lipid stores in skeletal muscle independent of weight changes (41)

What we know from phase 2 The 48-week phase 2 trial provided reassuring safety signals

ResM is non-GMO, sugar-free, gluten-free, vegan and contains all-natural ingredients